A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 7

Quantification of the ADCC activity of rituximab using iLite effector cells and CD20⁺ target cells or NFAT effector cells and WT Raji cells. Assay-ready frozen iLite effector cells (1.2 × 10⁵ cells/well) or thaw-and-use NFAT effector cells (1.2 × 10⁵ cells/well) and frozen assay-ready CD20⁺ target cells were mixed at an E:T ratio of 1 : 3 and 1 : 6, respectively, and incubated for 4 (a) or 6 hours (b) at 37°C in the presence of increasing concentrations of rituximab prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) or Bio GLO, respectively, and the sequential determination of FL and NL activity or FL activity alone. Results are expressed as fold induction relative to the control sample without rituximab.

(a)

(b)